Diagnosis and Treatment of Patients with Autoimmune Bullous Disorders in Germany

Dermatologic Clinics

Volumn 29, Issue 4, 2011, Pages 663-671

  Schmidt, Enno ^a   Zillikens, Detlef ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Autoantibody; Bullous; Pemphigoid; Pemphigus; Therapy

Indexed keywords

AZATHIOPRINE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; DEXAMETHASONE; DOXYCYCLINE; ETRETIN; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; PSORALEN; RITUXIMAB; TETRACYCLINE;

AUTOIMMUNE SKIN DISEASE; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; DERMATITIS HERPETIFORMIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMOLYSIS BULLOSA ACQUISITA; GERMANY; GLUTEN FREE DIET; HEALTH CARE SURVEY; HUMAN; IGA PEMPHIGUS; IMMUNOADSORPTION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; INCIDENCE; LICHEN PLANUS PEMPHIGOIDES; MUCOUS MEMBRANE PEMPHIGOID; NONHUMAN; PARANEOPLASTIC PEMPHIGUS; PEMPHIGOID; PEMPHIGOID GESTATIONIS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; ULTRAVIOLET A RADIATION;

ADRENAL CORTEX HORMONES; ANIMALS; AUTOIMMUNE DISEASES; CYCLOPHOSPHAMIDE; DAPSONE; DERMATOLOGIC AGENTS; DERMATOLOGY; GERMANY; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INSURANCE, HEALTH; RATS; SKIN DISEASES, VESICULOBULLOUS;

EID: 80052903850     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2011.06.007     Document Type: Review

References (35)

1. Hahn-Ristic K., Rzany B., Amagai M., et al. Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. J Eur Acad Dermatol Venereol 2002, 16:68-71.
2. Bertram F., Brocker E.B., Zillikens D., et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009, 7:434-440.
3. Zillikens D., Wever S., Roth A., et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 1995, 131:957-958.
4. Jung M., Kippes W., Messer G., et al. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol 1999, 41:266-268.
5. Schmidt E., Zillikens D. Diagnostic and therapy of autoimmune blistering diseases. Dtsch Arztbl Int 2011, 108:399-405.
6. Schmidt E., Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010, 10:84-89.
7. Goebeler M., Sitaru C., Zillikens D. J Dtsch Dermatol Ges 2004, 2:774-791.
8. Mutasim D.F. Management of autoimmune bullous diseases: pharmacology and therapeutics. J Am Acad Dermatol 2004, 51:859-877.
9. Khumalo N., Kirtschig G., Middleton P., et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2005, 3. CD002292.
10. Martin L.K., Werth V., Villanueva E., et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009, 1. CD006263.
11. Kasperkiewicz M., Schmidt E. Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 2009, 6:270-280.
12. Harman K.E., Albert S., Black M.M. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003, 149:926-937.
13. Wojnarowska F., Kirtschig G., Highet A.S., et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002, 147:214-221.
14. Chan L.S., Ahmed A.R., Anhalt G.J., et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002, 138:370-379.
15. Hofmann S.C., Kautz O., Hertl M., et al. Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J Dtsch Dermatol Ges 2009, 7:227-233.
16. Joly P., Roujeau J.C., Benichou J., et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009, 129:1681-1687.
17. Joly P., Roujeau J.C., Benichou J., et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346:321-327.
18. Rzany B., Partscht K., Jung M., et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002, 138:903-908.
19. Schmidt E., Kraensel R., Goebeler M., et al. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. Cutis 2005, 76:205-209.
20. Amagai M., Ikeda S., Shimizu H., et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009, 60:595-603.
21. Nagel A., Hertl M., Eming R. B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol 2009, 129:289-301.
22. Joly P., Mouquet H., Roujeau J.C., et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007, 357:545-552.
23. Ahmed A.R., Spigelman Z., Cavacini L.A., et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006, 355:1772-1779.
24. Schmidt E., Goebeler M., Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009, 1173:683-691.
25. Schmidt E., Goebeler M. CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab. Expert Rev Dermatol 2008, 3:259-278.
26. Schmidt E., Klinker E., Opitz A., et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003, 148:1222-1229.
27. Eming R., Rech J., Barth S., et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006, 212:177-187.
28. Shimanovich I., Bohmke A.K., Westermann L., et al. Successful treatment of severe pemphigus with the combination of immunoadsorption and rituximab. J Invest Dermatol 2009, 129:S97.
29. Shimanovich I., Nitschke M., Rose C., et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008, 158:382-388.
30. Shimanovich I., Herzog S., Schmidt E., et al. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 2006, 31:768-774.
31. Schmidt E., Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res 2010, 302:241-253.
32. Zillikens D., Derfler K., Eming R., et al. Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007, 5:881-887.
33. Hertl M., Zillikens D., Borradori L., et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008, 6:366-373.
34. Enk A., Fierlbeck G., French L., et al. Use of high-dose immunoglobulins in dermatology. J Dtsch Dermatol Ges 2009, 7:806-812.
35. Zimmermann J., Bahmer F., Rose C., et al. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges 2010, 8:598-605.